An N-of-1 randomized controlled trial ('N-of-1 trial') of donepezil in the treatment of non-progressive amnestic syndrome

Age Ageing. 2002 Jul;31(4):307-9. doi: 10.1093/ageing/31.4.307.

Abstract

Introduction: a professional man sustained a residual, persisting, isolated impairment of short-term memory secondary to severe carbon monoxide poisoning. Informal, open trial of the cholinesterase inhibitor donepezil resulted in uncertain benefit.

Protocol: an N-of-1 randomized, double-blind controlled trial of donepezil against placebo. Placebo-induced headache permitted evaluation of donepezil at only the 5 mg dose.

Results: there was no improvement in short-term memory.

Conclusion: the trial excluded significant benefit of donepezil 5 mg in this patient, preventing long-term unnecessary prescription. Beneficial effects in other similar patients or at higher dosage cannot be excluded.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Cholinesterase Inhibitors / adverse effects
  • Cholinesterase Inhibitors / therapeutic use*
  • Donepezil
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Humans
  • Indans / adverse effects
  • Indans / therapeutic use*
  • Memory, Short-Term*
  • Piperidines / adverse effects
  • Piperidines / therapeutic use*

Substances

  • Cholinesterase Inhibitors
  • Indans
  • Piperidines
  • Donepezil